Posts tagged cancer
Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have failed first line treatment, as well as patients with advanced pancreatic and ovarian cancers.

Read More
Profound makes leap to platform company from prostate product

With its recent acquisition of Royal Philips’ (NYSE:PHG; AEX:PHIA) Sonalleve business, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is making the leap from a medical device company focused on prostate cancer ablation to a platform company, offering real-time magnetic resonance (MR)-guidance as the imaging platform and ultrasound as the energy source for the delivery of non-invasive ablative technology to clinicians.

Read More
Zymeworks platforms validated by pharma partnerships

Zymeworks’ (NYSE, TSX:ZYME) marquee partnerships with Merck, Eli Lilly, Celgene, GlaxoSmithKline and Daiichi-Sankyo provide validation for its next-generation oncology platforms, with the potential for $4.1-billion in milestone payments.

Read More
In conversation with Lloyd Segal of Repare

As president and CEO of upstart Repare Therapeutics, Lloyd Segal was instrumental is arranging the initial funding to create Repare while he served as an entrepreneur-in-residence at Versant Ventures, a leading healthcare investment firm with a hands-on approach to company building. Repare is developing precision oncology drugs that target specific vulnerabilities of tumor cells...

Read More
Contextual Genomics detecting genetic mutations in cancer

Closely-held Contextual Genomics is giving oncologists a leg up to enhance cancer care with its new Find-It molecular test to detect genetic mutations in cancer patients.

Read More
Tetra Bio-Pharma sets active cannabis clinical programs

Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has an aggressive clinical trial program set to begin in the final quarter this year and first quarter of 2018 to prove the efficacy and safety of at least three therapeutic cannabis products.

Read More
FeatureLeonard ZehrTetra, Tetra Bio-Pharma, OTCQB, OTCQB:TBPMF, TBPMF, CSE, CSE:TBP, TBP, clinical trial, therapeutic cannabis products, cannabis, cannabis products, natural health cannabis, natural health, Andre Rancourt, topical treatment, pain management, cardiovascular disease, athletic performance, skin care, topical cream, sales and marketing, branding, distribution, Phyto Pain Pharma, cannabis-based drug products, Agro Tek, Grow Pros, marijuana, recreational marijuana company, global leader, nutraceuticals, toxic, toxic side effects, steroids, Health Canada, FDA, insurance companies, PPP001, smokeable marijuana, advanced cancer pain, cancer pain, cancer, pellet, titanium inhalation device, digital readout, consumption, Aphria, OTCQB:APHQF, APHQF, TSX, TSX:APH, APH, licensed producer, active pharmaceutical ingredient, Phase 1 study, safety data, pharmacokinetic data, tetrahydrocannabinol, THC, pain relief, cancer patients, Phase 1 trial, Phase 3 clinical trial, chemical entity, pivotal trial, Notice of Compliance, ACMPR, opioids, severe pain, IntelGenx, OTCQX, OTCQX:IGXT, IGXT, TSXV, TSXV:IGX, IGX, oral mucoadhesive, dronabinol XL tablet, cheek, AdVersa controlled-release technology, THC tablet, synthetic THC, North American patients, anorexia, cancer chemotherapy-related pain, chemotherapy-related pain, PPP002, Phase 2 trial, Division of Anesthesia, Analgesia, Addiction Products, and Addiction Products, 505(b)(2) regulatory filing, 505(b)(2), regulatory filing, Dronabinol XL AdVersa Mucoadhesive tablet, dry eye disorder, ocular pain, inflammation, Panag Pharma, proof-of-concept, cannabinoid eye drop, eye drop, PPP003, exema, general neuropathic pain, business model, pharmaceutical relevance
3DS’ genomic imaging for precision medicine

As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging software, known as TeloView, goes beyond identifying whether a patient suffers from a specific condition. By analyzing a patient’s chromosomal arrangement, or signature, TeloView can help doctors tailor personalized treatment and manage each individual patient. With two decades of executive life sciences management and start-up experience, including successive roles at Bayer and J&J, Mr. Flowerday’s mission at 3DS is to transform a highly promising platform technology into a commercial reality with U.S. partners, focus on those tests that can deliver early value and broaden the company’s development program. In this interview with BioTuesdays.com, Mr. Flowerday discusses recent advances in 3DS’ lead diagnostic programs and their application to drug development.

Read More
In conversation with Jason Kolbert

As head of healthcare research and as the senior biotechnology analyst with Maxim Group, Jason Kolbert has worked extensively in the healthcare sector. This includes pharma experience with Schering-Plough in Japan, as a fund manager and as an equity analyst for the past 20 years. 

Read More
Enumeral pursuing near-term collaborations

Wael Fayad, who moved into the executive suite of Enumeral (OTCQB:ENUM) as chairman, president and CEO at the end of September, plans to reboot the company in the near term through partnering and collaborations.

Read More
Micromedic seeking diagnostic partners on multiple fronts

With approvals in Europe and Israel for its CellDetect non-invasive test for recurrence of bladder cancer, Micromedic Technologies (TASE:MCTC) is seeking FDA approval for a pivotal trial expected to begin in the first quarter next year with bladder cancer patients.

Read More
Immunovaccine targets three clinical milestones

Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months.

Read More
BioSyent to target international markets

BioSyent (OTC:BIOYF; TSX-V:RX) is actively building its international pharmaceutical sales and marketing business, adding products licensed and sold internationally to products already being shipped from Canada.

“We’re working on a couple of international deals now,” René Goehrum, chairman, president and CEO, says in an interview with BioTuesdays.com.

Mr. Goehrum explains that BioSyent hopes to commercialize new product deals in the Middle East, Latin America and Southeast Asia. “These products may not be licensed for sale in Canada.”

Read More
In conversation with Jerry Ropelato

As CEO and founder of closely-held WhiteClouds, which operates the largest 3D color printing facility in the world, Jerry Ropelato is passionate about using the technology to create stunning models for the architecture, entertainment, retail and medical sectors. He points out that 3D printing is helping to further personalize healthcare and can play a pivotal role in helping doctors not only better tailor their care to each patient’s needs, but also in the way they devise diagnoses and treatment plans. In this interview with BioTuesdays.com, Mr. Ropelato discusses how his company is working with the health care sector.

Read More
Pivot Pharma seeks financing to develop drugs for women’s cancers

Upstart Pivot Pharmaceuticals (OTCQB:PVOTF), which was launched in the fourth quarter last year, is in talks with investors to raise up to $8-million in 2016 to initiate proof-of-concept studies for one of its two lead drug candidates for the treatment of endometrial and triple-negative breast cancers.

“These women’s cancers represent areas of high unmet medical need due to genomic mutations and our focus is to develop fast-to-market novel drugs that can be used in combination with other anticancer drugs,” CEO, Pravin Chaturvedi, says in an interview with BioTuesdays.com.

Funds raised this year also will be used to expand the company’s business development programs, including plans to acquire additional later-stage drug candidates for the treatment of women’s health.

Read More
BioLight Life Sciences focusing on ophthalmic portfolio

BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) is now defining itself as an ophthalmology company after spending several years assembling a cluster of investments in the sector as well as in cancer diagnostics.

“We believe there is a huge value potential from the ophthalmic therapeutics and diagnostics we have gathered,” CEO, Suzana Nahum Zilberberg, says in an interview with BioTuesdays.com.

“These technologies target diseases with unmet medical needs that require innovation to treat large and growing patient populations, especially in the elderly,” she adds.

While BioLight intends to retain its controlling ownership position in its Micromedic cancer diagnostics portfolio, “on a daily basis, we are focusing on ophthalmology,” she contends.

Read More
Concert starts multiple dose trial with CF drug

Concert Pharmaceuticals (NASDAQ:CNCE), which is modifying known drugs with its deuterium technology, last week initiated a multiple ascending dose Phase 1 trial with healthy volunteers of its next generation drug for cystic fibrosis (CF), CTP-656, as a stepping stone to a small Phase 2 efficacy trial in the second half of 2016.

“We hope to showcase how deuterium, a heavier form of hydrogen, can create new medicines from existing drugs to potentially enhance safety and efficacy as well as treat new indications,” Roger Tung, president and CEO, says in an interview with BioTuesdays.com.

The current trial will include three different doses of CTP-656 as well as a single dose crossover comparison of CTP-656 with Kalydeco, or ivacaftor, which is the first drug that treats the underlying cause rather than the symptoms of CF in patients with certain mutations of the disease.

Read More
KAHR Medical on financing trail to develop dual signaling proteins

Dr. Shani explains that DSP molecules are fusion proteins connecting an extracellular portion of a Type-1 membrane protein at the fusion protein’s N-terminus with an extracellular portion of a Type-2 membrane protein at the fusion protein’s C-terminus.

He says this enhanced architecture of DSP molecules creates fusion-proteins with two functional ends that allow the fused molecule to facilitate a unique mode-of-action with increased activity, specificity and therapeutic benefits that cannot be achieved by simply administering the DSP protein elements as separate units, he contends.

“With two functional ends, DSP drugs are capable of effecting two biological pathways at the same time and at the same site, so that both pathways are reinforcing each other,” he points out. “The bi-functional nature of DSP molecules also allow for dual targeting of both sides of the molecule to the same site to reduce toxicity as well as the ability to utilize two biomarkers for more personalized medicine.”

Read More
In conversation with Dr. Isaac Ciechanover

As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He was a former partner in the life sciences practice at Kleiner Perkins Caufield & Byers and spent a decade as Celgene’s executive director of business development, spearheading venture capital, licensing and M&A activities with an aggregate transaction value of more than $6.7-billion. Dr. Ciechanover started Atara for personal reasons when his mother, Atara Ciechanover, for whom the company is named, was sick with ovarian cancer and there were no new therapies to treat the disease. Mrs. Ciechanover passed away in 2012. In this interview with BioTuesdays.com, Dr. Ciechanover discusses the company’s clinical programs that target unique pathways and may pause or reverse patients’ underlying diseases.

Read More
Harvard Apparatus to file IND for regenerated trachea trial

Harvard Apparatus Regenerative Technology (NASDAQ:HART) plans to file an IND later this year for a pivotal trial of the world’s first regenerated trachea transplant in patients facing life-threatening trachea trauma and cancer.

“Our InBreathAirway Transplant System has been successful in six human compassionate cases and because we have great data from these cases, we believe our clinical risk could be greatly reduced,” CEO, David Green, says in an interview with BioTuesdays.com.

“That makes us pretty unique for a biotech company, knowing the technology works in humans before we go into clinical studies,” he adds.

Read More